Galectin Therapeutics is a biopharmaceutical company developing therapies for fibrotic diseases and cancer by targeting galectin proteins, particularly galectin-3. The company manufactures proprietary complex carbohydrates derived from plant products that bind and inhibit galectin proteins; its lead candidate, belapectin, is being developed primarily for metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, with a secondary focus on cancer immunotherapy in combination with checkpoint inhibitors. The company pursues clinical development programs for serious, life-threatening diseases with limited treatment options, operates with a lean internal team supplemented by contractors, and outsources manufacturing and research execution to third-party providers while holding significant patent protection for its core compounds.